Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit
Authors:
- Wojciech KrajewskiWojciech Krajewski
- Marco MoschiniMMMarco Moschini
- Łukasz NowakŁNŁukasz Nowak
- Sławomir PoletajewSPSławomir Poletajew
- Andrzej TukiendorfAndrzej Tukiendorf
- Luca AfferiLALuca Afferi
- Jeremy TeohJeremy Teoh
- Tim MuilwijkTMTim Muilwijk
- Steven JoniauSteven Joniau
- Alessandro TafuriATAlessandro Tafuri
- Alessandro AntonelliAlessandro Antonelli
- Alessandra GozzoAGAlessandra Gozzo
Open Access
- 15 October 2020
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (10) , 3306
Abstract
Background and Purpose: The European Association of Urology guidelines recommend restaging transurethral resection of bladder tumours (reTURB) 2–6 weeks after primary TURB. However, in clinical practice some patients undergo a second TURB procedure after Bacillus Calmette-Guérin immunotherapy (BCG)induction. To date, there are no studies comparing post-BCG reTURB with the classic pre-BCG approach. The aim of this study was to assess whether the performance of reTURB after BCG induction in T1HG bladder cancer is related to potential oncological benefits. Materials and Methods: Data from 645 patients with primary T1HG bladder cancer treated between 2001 and 2019 in 12 tertiary care centres were retrospectively reviewed. The study included patients who underwent reTURB before BCG induction (Pre-BCG group: 397 patients; 61.6%) and those who had reTURB performed after BCG induction (Post-BCG group: 248 patients, 38.4%). The decision to perform reTURB before or after BCG induction was according to the surgeon’s discretion, as well as a consideration of local proceedings and protocols. Due to variation in patients’ characteristics, both propensity-score-matched analysis (PSM) and inverse-probability weighting (IPW) were implemented. Results: The five-year recurrence-free survival (RFS) was 64.7% and 69.1% for the Pre- and Post-BCG groups, respectively, and progression-free survival (PFS) was 82.7% and 83.3% for the Pre- and Post-BCG groups, respectively (both: p > 0.05). Similarly, neither RFS nor PFS differed significantly for a five-year period or in the whole time of observation after the PSM and IPW matching methods were used. Conclusions: Our results suggest that there might be no difference in recurrence-free survival and progression-free survival rates, regardless of whether patients have reTURB performed before or after BCG induction.Keywords
This publication has 19 references indexed in Scilit:
- [Clinical significance of residual tumors at repeat transurethral resection in patients with T1 bladder cancer].Zhonghua Yi Xue Za Zhi, 2016
- EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-GuérinEuropean Urology, 2016
- The impact of re‐transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high‐grade/Grade 3 bladder cancer treated with bacille Calmette–GuérinBJU International, 2015
- Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high‐risk non‐muscle‐invasive bladder cancer treated with maintenance intravesical Bacillus Calmette‐GuérinBJU International, 2015
- Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancerNature Reviews Urology, 2015
- Tumour stage on re-staging transurethral resection predicts recurrence and progression-free survival of patients with high-risk non-muscle invasive bladder cancerCanadian Urological Association Journal, 2014
- Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resectionBJU International, 2012
- Propensity scores and M‐structuresStatistics in Medicine, 2009
- Variability in the Recurrence Rate at First Follow-up Cystoscopy after TUR in Stage Ta T1 Transitional Cell Carcinoma of the Bladder: A Combined Analysis of Seven EORTC StudiesEuropean Urology, 2002
- THE VALUE OF A SECOND TRANSURETHRAL RESECTION IN EVALUATING PATIENTS WITH BLADDER TUMORSJournal of Urology, 1999